Breaking up with Pfizer is hard to do, Zoetis chief says, but worth it

Why do Russians prefer cats to dogs? Which livestock drugs are growing fastest? And what are the benefits of being separate from Pfizer? Juan Ramón Alaix, CEO of the Zoetis ($ZTS) animal health business Pfizer ($PFE) spun off early this year, answers these and other questions in a Wall Street Journal interview. Report (sub. req.)